DA Davidson Upgrades Medifast to Neutral, Raises Price Target to $17
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
DA Davidson analyst Linda Bolton Weiser upgrades Medifast (NYSE:MED) from Underperform to Neutral and raises the price target from $16.5 to $17.
DA Davidson analyst Linda Bolton Weiser upgrades Medifast (NYSE:MED) from Underperform to Neutral and raises the price target from $16.5 to $17.